<p>AMF Tjanstepension AB 在第三季度增持了 Kenvue Inc.（NYSE: KVUE - Free Report）的持股，持股比例增加了 187.3%，根据该公司最近向 SEC 提交的文件。该基金在本季度购买了额外的 78,540 股后，持有该公司股票的 120,477 股。AMF Tjanstepension AB 在最新报告期结束时持有的 Kenvue 股份价值 278.7 万美元。</p>
<ul>
<li>锁定收益：3 只股息股票有望很快提高派息</li>
</ul>
<p>其他大型投资者也对该公司的持股进行了调整。Vanguard Group Inc.在第一季度增持了 Kenvue 的持股 12.0%。Vanguard Group Inc.现在拥有公司股票 1 亿 6,678.9 万股，价值 35.79 亿美元，在上个季度额外增持了 1,790.8 万股。Price T Rowe Associates Inc. MD 在第一季度增持了 Kenvue 的持股 23.1%。Price T Rowe Associates Inc. MD 现在拥有公司股票 1 亿 3,456.5 万股，价值 28.88 亿美元，在上个季度额外增持了 2,523.8 万股。马萨诸塞金融服务公司在第二季度增持了 Kenvue 的持股 9.6%。马萨诸塞金融服务公司现在拥有公司股票 7,986.4 万股，价值 14.52 亿美元，在上个季度额外增持了 702.3 万股。威灵顿管理集团在第四季度增持了 Kenvue 的持股 6.7%。威灵顿管理集团现在拥有公司股票 7,650.2 万股，价值 16.47 亿美元，在该时期额外购买了 481.5 万股。最后，摩根大通在第一季度增持了 Kenvue 的持股 11.1%。摩根大通现在拥有公司股票 6,831.9 万股，价值 14.66 亿美元，在该时期额外购买了 682.6 万股。机构投资者拥有该公司股份的 97.64%。</p>
<h2>Kenvue 股票表现</h2>
<p>NYSE: KVUE 的股价周五开盘为 22.27 美元。该公司的市值为 426.4 亿美元，市盈率为 28.55，市盈增长比为 2.92，贝塔系数为 1.40。该公司的 50 天简单移动平均线为 21.77 美元，200 天简单移动平均线为 20.14 美元。该公司的资产负债比为 0.69，流动比率为 0.99，速动比率为 0.68。Kenvue Inc.的 52 周最低价为 17.67 美元，52 周最高价为 23.55 美元。</p>
<ul>
<li>这家医疗巨头的股票反弹：最低涨幅为 15%</li>
</ul>
<p>Kenvue（NYSE: KVUE - Get Free Report）最近公布了其截至 8 月 6 日星期二的季度收益结果。该公司报告本季度每股盈利为 0.32 美元，超过分析师预期的 0.28 美元，超出 0.04 美元。该季度业务收入为 40 亿美元，高于 39.3 亿美元的共识预期。Kenvue 的净利润率为 7.23%，净资产回报率为 21.80%。Kenvue 本季度的收入同比下降了 0.3%。去年同期，该公司每股盈利为 0.32 美元。作为一组，卖方分析师预测 Kenvue Inc.今年将实现每股 1.08 美元的盈利。</p>
<h2>Kenvue 增加股息</h2>
<p>该公司最近宣布了季度股息，于 8 月 28 日星期三支付。截至 8 月 14 日星期三持股的投资者将获得每股 0.205 美元的股息。这代表年化基础上的 0.82 美元股息和 3.68% 的收益率。这比 Kenvue 先前的季度股息 0.20 美元有所提高。Kenvue 的股息支付比率目前为 105.13%。</p>
<h2>分析师升级和降级</h2>
<ul>
<li>强生公司的股价已经便宜到极致</li>
</ul>
<p>许多研究公司发布了关于 KVUE 的报告。加拿大皇家银行将 Kenvue 的股票评级从 “跑赢市场” 调降至 “行业表现”，并设定了该股票的目标价为 24.00 美元。摩根大通将 Kenvue 的目标价从 22.00 美元上调至 24.00 美元，并给予该公司 “超配” 评级。德意志银行将 Kenvue 的目标价从 23.00 美元上调至 24.00 美元，并给予该公司 “买入” 评级。派杰桑德勒将 Kenvue 的目标价从 20.00 美元上调至 21.00 美元，并给予该公司 “中性” 评级。最后，杰富瑞金融集团在一份研究报告中开始对 Kenvue 的股票进行覆盖。他们给予该股票 “买入” 评级，并设定了 27.00 美元的目标价。一位投资分析师对该股票进行了卖出评级，七家公司对该股票持有评级，三家公司对该股票给予买入评级。根据 MarketBeat 的数据，Kenvue 的平均评级为 “持有”，目标价为 22.10 美元。</p>
<p><strong>阅读我们关于 KVUE 的最新股票分析</strong></p>
<h2>Kenvue 公司简介（免费报告）</h2>
<p>Kenvue Inc 是一家全球消费者健康公司。该公司通过三个部门运营：自我护理、皮肤健康与美容以及基本健康。自我护理部门提供泰诺、莫替、必理、尼古丁替代品、Zarbee's、ORSLTM、莱诺可、卡波尔和仪得等品牌的咳嗽、感冒和过敏、止痛、消化健康、戒烟、眼部护理和其他产品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票胜过 Kenvue</li>
<li>什么是 Euro STOXX 50 指数？</li>
<li>什么时候是投资共同基金的最佳时机？</li>
<li>最大的股票跌幅者 - 今日最大百分比跌幅者</li>
<li>NVIDIA 股票是在修正还是整理？</li>
<li>沃伦·巴菲特的 3 只股票现在就买</li>
<li>3 只超卖股票具有巨大的 RSI 反弹潜力</li>
</ul>
<p><strong>想看看其他对 KVUE 持有的对冲基金？</strong> 访问 HoldingsChannel.com 获取 Kenvue Inc.（NYSE: KVUE - Free Report）的最新 13F 申报和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUtWVUU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUtWVUU"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 我们在 2016 年推荐了英伟达，现在我们推荐这个...（来自 Porter &amp; Company）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njk3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njk3"/></p>
<h2>现在是否值得投资$1,000 在 Kenvue？</h2>
<p>在考虑 Kenvue 之前，您应该听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而 Kenvue 不在名单上。</p>
<p>尽管 Kenvue 目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

KVUE

<p>AMF Tjanstepension AB 在第三季度将其在 Kenvue Inc.（NYSE: KVUE）的持股增加了 187.3％，收购了额外的 78,540 股，使其总持股量达到 120,477 股。包括 Vanguard 和 Price T Rowe Associates 在内的其他机构投资者也增加了他们的持股。Kenvue 的股价开盘为 27.27 美元，市值为 640 亿美元，市盈率为 28.55。该公司最近宣布将季度股息提高至每股 0.205 美元，股息率为 3.68％。分析师对 Kenvue 的评级褒贬不一，目标股价差异较大</p>

<p>AMF Tjanstepension AB lifted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 187.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 120,477 shares of the company's stock after purchasing an additional 78,540 shares during the quarter. AMF Tjanstepension AB's holdings in Kenvue were worth $2,787,000 at the end of the most recent reporting period.</p>
<ul>
<li>Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon</li>
</ul>
<div class="lb-trans"><p>AMF Tjanstepension AB 在第三季度增持了 Kenvue Inc.（NYSE: KVUE - Free Report）的持股，持股比例增加了 187.3%，根据该公司最近向 SEC 提交的文件。该基金在本季度购买了额外的 78,540 股后，持有该公司股票的 120,477 股。AMF Tjanstepension AB 在最新报告期结束时持有的 Kenvue 股份价值 278.7 万美元。</p>
<ul>
<li>锁定收益：3 只股息股票有望很快提高派息</li>
</ul>
</div><p>Other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Kenvue by 12.0% during the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company's stock worth $3,579,294,000 after acquiring an additional 17,908,497 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Kenvue by 23.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company's stock worth $2,887,773,000 after acquiring an additional 25,238,112 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 9.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company's stock worth $1,451,927,000 after acquiring an additional 7,023,047 shares during the last quarter. Wellington Management Group LLP lifted its position in Kenvue by 6.7% during the 4th quarter. Wellington Management Group LLP now owns 76,501,956 shares of the company's stock valued at $1,647,087,000 after purchasing an additional 4,815,126 shares during the period. Finally, JPMorgan Chase &amp; Co. lifted its position in Kenvue by 11.1% during the 1st quarter. JPMorgan Chase &amp; Co. now owns 68,319,998 shares of the company's stock valued at $1,466,147,000 after purchasing an additional 6,825,611 shares during the period. Institutional investors own 97.64% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者也对该公司的持股进行了调整。Vanguard Group Inc.在第一季度增持了 Kenvue 的持股 12.0%。Vanguard Group Inc.现在拥有公司股票 1 亿 6,678.9 万股，价值 35.79 亿美元，在上个季度额外增持了 1,790.8 万股。Price T Rowe Associates Inc. MD 在第一季度增持了 Kenvue 的持股 23.1%。Price T Rowe Associates Inc. MD 现在拥有公司股票 1 亿 3,456.5 万股，价值 28.88 亿美元，在上个季度额外增持了 2,523.8 万股。马萨诸塞金融服务公司在第二季度增持了 Kenvue 的持股 9.6%。马萨诸塞金融服务公司现在拥有公司股票 7,986.4 万股，价值 14.52 亿美元，在上个季度额外增持了 702.3 万股。威灵顿管理集团在第四季度增持了 Kenvue 的持股 6.7%。威灵顿管理集团现在拥有公司股票 7,650.2 万股，价值 16.47 亿美元，在该时期额外购买了 481.5 万股。最后，摩根大通在第一季度增持了 Kenvue 的持股 11.1%。摩根大通现在拥有公司股票 6,831.9 万股，价值 14.66 亿美元，在该时期额外购买了 682.6 万股。机构投资者拥有该公司股份的 97.64%。</p>
</div><h2>Kenvue Stock Performance</h2>
<div class="lb-trans"><h2>Kenvue 股票表现</h2>
</div><p>Shares of NYSE:KVUE opened at $22.27 on Friday. The company has a market capitalization of $42.64 billion, a price-to-earnings ratio of 28.55, a P/E/G ratio of 2.92 and a beta of 1.40. The firm's 50 day simple moving average is $21.77 and its 200 day simple moving average is $20.14. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.55.</p>
<ul>
<li>This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum</li>
</ul>
<div class="lb-trans"><p>NYSE: KVUE 的股价周五开盘为 22.27 美元。该公司的市值为 426.4 亿美元，市盈率为 28.55，市盈增长比为 2.92，贝塔系数为 1.40。该公司的 50 天简单移动平均线为 21.77 美元，200 天简单移动平均线为 20.14 美元。该公司的资产负债比为 0.69，流动比率为 0.99，速动比率为 0.68。Kenvue Inc.的 52 周最低价为 17.67 美元，52 周最高价为 23.55 美元。</p>
<ul>
<li>这家医疗巨头的股票反弹：最低涨幅为 15%</li>
</ul>
</div><p>Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.04. The business had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. Kenvue's revenue for the quarter was down .3% on a year-over-year basis. During the same period last year, the company posted $0.32 EPS. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current year.</p>
<div class="lb-trans"><p>Kenvue（NYSE: KVUE - Get Free Report）最近公布了其截至 8 月 6 日星期二的季度收益结果。该公司报告本季度每股盈利为 0.32 美元，超过分析师预期的 0.28 美元，超出 0.04 美元。该季度业务收入为 40 亿美元，高于 39.3 亿美元的共识预期。Kenvue 的净利润率为 7.23%，净资产回报率为 21.80%。Kenvue 本季度的收入同比下降了 0.3%。去年同期，该公司每股盈利为 0.32 美元。作为一组，卖方分析师预测 Kenvue Inc.今年将实现每股 1.08 美元的盈利。</p>
</div><h2>Kenvue Increases Dividend</h2>
<div class="lb-trans"><h2>Kenvue 增加股息</h2>
</div><p>The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.68%. This is a boost from Kenvue's previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, August 14th. Kenvue's dividend payout ratio is presently 105.13%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，于 8 月 28 日星期三支付。截至 8 月 14 日星期三持股的投资者将获得每股 0.205 美元的股息。这代表年化基础上的 0.82 美元股息和 3.68% 的收益率。这比 Kenvue 先前的季度股息 0.20 美元有所提高。Kenvue 的股息支付比率目前为 105.13%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<ul>
<li>Johnson &amp; Johnson is as Cheap as it’s Going to Get</li>
</ul>
<div class="lb-trans"><h2>分析师升级和降级</h2>
<ul>
<li>强生公司的股价已经便宜到极致</li>
</ul>
</div><p>A number of research firms have issued reports on KVUE. Royal Bank of Canada downgraded shares of Kenvue from an &#34;outperform&#34; rating to a &#34;sector perform&#34; rating and set a $24.00 target price on the stock. in a research report on Tuesday, September 24th. JPMorgan Chase &amp; Co. upped their target price on shares of Kenvue from $22.00 to $24.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, August 7th. Piper Sandler upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a &#34;neutral&#34; rating in a research report on Monday, September 23rd. Finally, Jefferies Financial Group began coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a &#34;buy&#34; rating and a $27.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, Kenvue has an average rating of &#34;Hold&#34; and a consensus price target of $22.10.</p>
<div class="lb-trans"><p>许多研究公司发布了关于 KVUE 的报告。加拿大皇家银行将 Kenvue 的股票评级从 “跑赢市场” 调降至 “行业表现”，并设定了该股票的目标价为 24.00 美元。摩根大通将 Kenvue 的目标价从 22.00 美元上调至 24.00 美元，并给予该公司 “超配” 评级。德意志银行将 Kenvue 的目标价从 23.00 美元上调至 24.00 美元，并给予该公司 “买入” 评级。派杰桑德勒将 Kenvue 的目标价从 20.00 美元上调至 21.00 美元，并给予该公司 “中性” 评级。最后，杰富瑞金融集团在一份研究报告中开始对 Kenvue 的股票进行覆盖。他们给予该股票 “买入” 评级，并设定了 27.00 美元的目标价。一位投资分析师对该股票进行了卖出评级，七家公司对该股票持有评级，三家公司对该股票给予买入评级。根据 MarketBeat 的数据，Kenvue 的平均评级为 “持有”，目标价为 22.10 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on KVUE</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 KVUE 的最新股票分析</strong></p>
</div><h2>Kenvue Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Kenvue 公司简介（免费报告）</h2>
</div><p>Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.</p>
<div class="lb-trans"><p>Kenvue Inc 是一家全球消费者健康公司。该公司通过三个部门运营：自我护理、皮肤健康与美容以及基本健康。自我护理部门提供泰诺、莫替、必理、尼古丁替代品、Zarbee's、ORSLTM、莱诺可、卡波尔和仪得等品牌的咳嗽、感冒和过敏、止痛、消化健康、戒烟、眼部护理和其他产品。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Kenvue</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>When Is the Best Time to Invest in Mutual Funds?</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Is NVIDIA Stock in a Correction or Consolidation?</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票胜过 Kenvue</li>
<li>什么是 Euro STOXX 50 指数？</li>
<li>什么时候是投资共同基金的最佳时机？</li>
<li>最大的股票跌幅者 - 今日最大百分比跌幅者</li>
<li>NVIDIA 股票是在修正还是整理？</li>
<li>沃伦·巴菲特的 3 只股票现在就买</li>
<li>3 只超卖股票具有巨大的 RSI 反弹潜力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding KVUE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 KVUE 持有的对冲基金？</strong> 访问 HoldingsChannel.com 获取 Kenvue Inc.（NYSE: KVUE - Free Report）的最新 13F 申报和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUtWVUU" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=KVUE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ We recommended Nvidia in 2016, now we’re recommending this… (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 我们在 2016 年推荐了英伟达，现在我们推荐这个...（来自 Porter &amp; Company）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njk3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9697&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Kenvue right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Kenvue？</h2>
</div><p>Before you consider Kenvue, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kenvue 之前，您应该听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而 Kenvue 不在名单上。</p>
</div><p>While Kenvue currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Kenvue 目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

AMF Tjanstepension AB 购买了 78,540 股 Kenvue Inc.（NYSE:KVUE）的股票